Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial

Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial

Abstract Evidence from Europe shows that perioperative chemotherapy may be beneficial for the treatment of locally advanced gastric cancer, but reliable and robust data is lacking. To rectify this, the phase 3 RESONANCE trial investigated the efficacy and safety of S-1 plus oxaliplatin (SOX) as a pe...

Full description

Bibliographic Details
Main Authors: Xinxin Wang, Canrong Lu, Bo Wei, Shuo Li, Ziyu Li, Yingwei Xue, Yingjiang Ye, Zhongtao Zhang, Yihong Sun, Han Liang, Kai Li, Linghua Zhu, Zhichao Zheng, Yanbing Zhou, Yulong He, Fei Li, Xin Wang, Pin Liang, Hua Huang, Guoli Li, Xian Shen, Jiafu Ji, Yun Tang, Zekuan Xu, Lin Chen, on behalf of RESONANCE study group
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Journal of Hematology & Oncology
Subjects:
Gastric cancer
Perioperative
Adjuvant
Chemotherapy
S-1
Oxaliplatin
Online Access:https://doi.org/10.1186/s13045-024-01536-7

Internet

https://doi.org/10.1186/s13045-024-01536-7

Similar Items